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ABSTRACT
Objective To examine health professionals’ experiences
ofandattitudestowardstheprovisionofchemotherapyto
patients with end stage cancer.
Design Purposive, qualitative design based on in-depth
interviews.
SettingOncologydepartmentsatuniversityhospitalsand
general hospitals in the Netherlands.
Participants 14 physicians and 13 nurses who cared for
patients with metastatic cancer.
Results Physicians and nurses reported trying to inform
patients fully about their poor prognosis and treatment
options. They would carefully consider the (side) effects
ofchemotherapyandsometimesdoubtedwhetherfurther
treatment would contribute to patients’ quality of life.
Both groups considered the patients’ wellbeing to be
important, and physicians seemed inclined to try to
preserve this by offering further chemotherapy, often
followed by the patient. Nurses were more often inclined
toexpresstheirdoubtsaboutfurthertreatment,preferring
to allow patients to make the best use of the time that is
left. When confronted with a treatment dilemma and a
patient’swishfortreatment,physicianspreferredtomake
compromises, such as by “trying out one dose.”
Discussingdeathordyingwithpatientswhileatthesame
time administering chemotherapy was considered
contradictory as this could diminish the patients’ hope.
Conclusions The trend to greater use of chemotherapy at
the end of life could be explained by patients’ and
physicians’mutuallyreinforcingattitudesof“notgivingup”
andbyphysicians’broadinterpretationofpatients’quality
of life, in which taking away patients’ hope by withholding
treatment is considered harmful. To rebalance the ratio of
quantity of life to quality of life, input from other health
professionals, notably nurses, may be necessary.
INTRODUCTION
The progress in the treatment of many cancers is
substantial.
12 With new, more effective treatment
options, deciding about treatment at the end of life has
become a delicate process. In general, when a curative
goal has become unfeasible, the goal of treatment is to
delayandrelievetumourrelatedsymptoms.Inthecase
of chemotherapy (the most commonly used treatment
option), however, these goals are often at the price of
serious side effects such as nausea and fatigue. With
end stage cancer, another possible consequence of
further treatment is that patients are prevented from
preparing themselves for death.
3 Putting too much
emphasis on the prolonging of life could therefore
havea negativeoutcome, andpossible overuse oftreat-
ment is now widely debated in the medical arena.
4-7
The trend towards increasing use of chemotherapy
attheendoflifehasbeendescribedas“atrendtowards
the aggressiveness in cancer care.”
589 It is frequently
investigated in relation to the quality of care provided
to patients with metastatic cancer because overly
aggressivetreatmenthasbeenidentifiedasanindicator
of poor quality of care.
5 However, severely ill patients
sometimes wish for chemotherapy even when such
treatment is probably ineffective.
10 It is a physician’s
professional duty only to provide treatment that is in
thepatient’sinterest.
11However,inapluralisticsociety
in which patient autonomy is a key value, it is not a
priori clear what “the patient’s interest” involves.
12 It
could be argued that, by respecting patients’ informed
preferences concerning end of life treatment, any dis-
agreement between patient and doctor may be
resolved. However, Mack et al recently showed that
carers reported better ratings for quality of life in can-
cerpatientswhoinitiallypreferredlifeprolongingcare
(including chemotherapy) but eventually did not
receivesuchcareinthelastweekoflifethaninpatients
who did receive such care.
13 Because of their profes-
sional skills and experience, doctors may be better at
judging patients’ wellbeing than they are themselves.
Healthprofessionals’thoughtsaboutthebenefitsand
burdens of chemotherapy in end stage cancer are lar-
gelyunknown.Wethereforeinvestigatedhealthprofes-
sionals’ experiences of and attitudes towards the use of
chemotherapyattheendoflife,andtriedtorelatethese
findings tothe depicted trend towards increasing use of
chemotherapy. We interviewed physicians and nurses,
having different responsibilities towards the patients,
who had cared for patients with metastatic cancer.
METHODS
Design and setting
This study is the qualitative part of a larger research
project to investigate the role of medical professionals
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present study we interviewed physicians and nurses
who cared for patients diagnosed with metastatic can-
cer. Qualitative interviews are particularly useful for
exploring doctors’ and nurses’ own ideas, as they
give respondents the opportunity to address themes
that the researchers may not have anticipated.
14 We
recruited physicians and nurses from university hospi-
tals and general hospitals.
Recruitment and sampling
Physicians
Participants were purposely
14 sampled to represent a
widerangeinmedicalspecialties,age,andsextoreflect
the possible diversity of opinions. In four hospitals
(two academic hospitals and two general hospitals) a
contact person at the oncology department provided
us with names of physicians who were willing or likely
to participate in the study. Furthermore, three physi-
cians were recruited through a “snowball technique”;
one of those physicians had recently worked in a uni-
versityhospitalbutwaspresentlyworkinginahospice,
another physician combined hospice work with his
work in a general hospital.
Nurses
Asimilarprocedurewasfollowedtorecruitthenurses.
In the same four hospitals, a contact person provided
us with names of nurses who were willing or likely to
participate in the study. We recruited nurses working
at the inpatient unit (where patients can stay for a
while), nurses working at the outpatient unit (where
patients come only to receive chemotherapy), and
research nurses (responsible for experimental treat-
ment with chemotherapy). Again, we sought maxi-
mum variety with respect to age and sex.
Interviews
DataforthisstudywerecollectedfromJunetoOctober
2010 through face to face, semi-structured interviews
that lasted an average of 40 minutes (standard devia-
tion10minutes)forthephysiciansand35(10)minutes
for the nurses. All interviews took place in each physi-
cian’s or nurse’s practice. We approached the partici-
pants by telephone or email, and the primary
researcher(HMB) explainedthe studyaims and meth-
ods. Each participant also received an information
sheet. Interviews were held until data saturation was
reached.
15 HMB conducted a total of 14 interviews
withphysiciansand13interviewswithnurses.Accord-
ing to Dutch policy, the study did not require a review
byanethicscommitteebecausethedatacollectionwas
anonymouswithregardtotheparticipantsandthecon-
tentoftheinterviewswasnotconsideredtobepossibly
incriminating.
Weusedsemi-structuredtopiclistsfortheinterviews
that were based on a topic list of earlier work. That list
began with general questions about the health profes-
sional’sbackground;thenopenendedquestionsabout
thehealthprofessional’sgeneralexperienceswithcare
and treatment decisions; and finally questions about
two patients whom the respondent had personally
lookedafterandwhohadalreadydied.
16Inthepresent
study,itconcernedonepatientwithwhomthecommu-
nication about treatment had been rather straightfor-
ward and one with whom dilemmas had arisen as to
whether (additional) treatment should be given. In
the present study, we tried to address similar topics
for the physicians and nurses as far as possible.
Several issues were explored—the decision making
process,thedistinctionbetweencurativeandpalliative
care, the way treatment alternatives and the option of
“doingnothing”cameupduringconsultations,theper-
ceived role of nurses in treatment decisions, the way
nurses were informed about physicians’ treatment
policies, discussions about death and dying and their
ideas about futile practice in oncology. We did not use
any specific definition when we spoke about “treat-
ment” but evaluated what the respondent actually
meant during the interview. (In the Results section of
this paper, however, the term “treatment” means pal-
liative chemotherapy unless stated otherwise.) We stu-
diedphysicians’andnurses’experiencesofalltypesof
cancer patients, but always took into account the type
of cancer of the patients concerned, as the cancer tra-
jectories, such as the time until death, may vary. The
most common cancer types discussed were cancers of
the colon, pancreas, breast, lung, and prostate.
All respondents consented to the interview being
audiotaped.Theinterviewsweretranscribedverbatim.
Analysis
The first available data (two interviews within each of
the physician and nurse respondent groups) were dis-
cussedbyamultidisciplinaryprojectgroupwithexper-
tise in health sciences, sociology, medical
anthropology, and ethics (HMB, MLR, GdH, HW,
K Davis, and M Stapel). These discussions led to
rephrasing and a different ordering of some of the
questions on the topic list. In addition, questions were
addedthattriggeredphysiciansandnursestogivetheir
personal opinions about patients who wanted to con-
tinue with treatment until the very end, and patients
whorefusedalltreatmenteventhoughitwouldbeben-
eficial.
Dataanalysiswasinformedbyqualitativemethodol-
ogy, based on a constant comparison approach.
1517
After having interviewed sufficient respondents, we
(HMB and MLR) independently read through five
interviews in each respondent group to identify gen-
eral themes, and then to identify specific categories
within the themes to check for interpreter consensus
concerning the assignment of text fragments to major
themes. Together, we discussed these themes until we
reached consensus. We then rephrased some of the
questions and put different emphasis on some of the
items in the topic list: although we asked respondents
about all treatment decisions that had been made, we
focused more on the decision when further treatment
waswithheld.HMBsubsequentlycodedtheremaining
interviews. We later discussedour findings with differ-
entmembersoftheprojectgroup,andworkedtowards
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HMB checked these interpretations with the existing
data. LvZ finally evaluated whether the quotes were
used in the right medical context. All data were ana-
lysed with qualitative research software (Atlas.ti
6.1.12). A professional translator translated the quotes
that we eventually chose to illustrate our results.
RESULTS
Respondent characteristics
We tried to contact 22 physicians for an interview.
Six declined and two could not be contacted, leaving
14 physicians to be interviewed(see table). These phy-
sicians had an average age of 41 years, and eight were
women. Work experience within oncology varied,
with seven having less than five years’ experience.
We approached 13 nurses for an interview, all of
whom agreed to participate (table). Their average age
was 40 years, 11 were women, and seven had had spe-
cial education in oncology.
Qualitative findings
We identified four domains that provided insight into
the use of chemotherapy for patients with metastatic
cancer:rationalargumentstoprescribechemotherapy,
the phenomenon of cooperative patients and coopera-
tive physicians, ambivalence, and ways to interrupt
patients’ and physicians’ mutually reinforcing atti-
tudes of “not giving up.”
Rational arguments to prescribe chemotherapy
Physicians and nurses clearly differentiated a curative
approach from a palliative approach. They reported
that, with a palliative approach, it is more important
to look critically whether the (side) effects make it
worth going ahead with treatment. They agreed that
patients need to be informed about the approach.
“Yes, I think the distinction [between a palliative
and curative approach] is always extremely
important. I think it is important for the patient to
know that, but it also has a tremendous impact on
the way you administer the course of treatment.…
In the case of palliative treatment, a holiday
awkwardly planned in the middle of that treatment
suddenly becomes nevertheless very important so
that you have to adapt the treatment schedule
accordingly.”—Physician 9 (general hospital)
Not surprisingly, physicians and nurses reported
that they would initially focus on disease modifying
treatments (mostly chemotherapy) to diminish
patients’ symptoms and prolong life. They accepted
that it was sometimes necessary for patients to experi-
ence severe side effects of treatment for a relatively
short period to live a longer life. Actively treating
patients with recently diagnosed metastatic cancer
was thus an obvious thing to do.
“And ‘palliative’ can sometimes, of course, take
quite a long time; we’re talking at least about a few
years, definitely in the case of breast cancer or other
cancers for that matter, so people can really be quite
fit.”—Physician 6 (university hospital)
However, when cancer had progressed despite che-
motherapy, physicians’ approaches to choosing when
and whether to prescribe further treatment varied.
Some physicians said they waited for patients’ symp-
toms to develop before prescribing chemotherapy,
whereas others reported prescribing chemotherapy in
the absence of symptoms. They all highly valued
patients’ quality of life, but the moment they chose to
prescribe further chemotherapy seemed to depend
more on the importance they attached to prolonging
a patient’s life.
“Because if you say, ‘We’d be better off waiting
until there are symptoms,’ people find that quite
strange, because, after all, ‘I’ve come at an early
stage and I want treatment now.’… And then I
think, as a physician, you tend to be fairly quickly
inclined, after all, to start chemotherapy earlier than
perhaps would be strictly indicated clinically
speaking.... I do think that people really must have
symptoms which I think ‘can be combated with
chemotherapy,’ yes.”—Physician 8 (general
hospital)
Table 1 |Characteristics of health professionals interviewed about the use of chemotherapy
for cancer patients at the end of life
Physicians (n=14) Nurses (n=13)
Mean (SD) age (years) 41 (8) 40 (8)
Sex (men:women) 6:8 2:11
Setting:
University hospital 6 7
General hospital 8 6
Specialty of physician:
Internal medicine, oncology, or haematology* 12 —
Oncology with special education in palliative care† 2 —
Specialty of nurse:
General — 3
Oncology — 7
Research — 3
Work experience within oncology (years):
0–57 2
5–10 3 4
>10 4 7
Physicians’ most difficult situation during treatment‡:
Patients insisting on having treatment despite low
chance of response
8 —
Patients refusing all treatment options despite high
chance of response
3 —
Both situations are difficult, if in the extreme 3 —
*All had followed courses on palliative care.
†Both physicians worked in a university hospital and were appointed to take care of cancer patients in the last
stage of life. They were thus primarily responsible for pain and symptom management. One physician was also
an oncologist; the other was primarily responsible for palliative care.
‡Physicians were asked, in an open ended question, about their most difficult situations during treatment. Two
situations could be distinguished:
(1) Patients who persisted in wanting treatment. “I personally have greater difficulty with patients who want to
continue treatment come what may. I sometimes think, ‘Call it a day. For goodness’ sake, try to enjoy the time
you have left.’”—Physician 7 (university hospital)
(2) Patients who refused all possible treatment options. “No, if they don’t want to. If I think that someone could
really benefit from it [treatment] without too many problems, and they really don’t want to…. It is much more
difficult if they don’t want to go on.”—Physician 14 (general hospital)
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but for me the most important thing is quality of
life. And in his case it was good, so you provide
treatment in the hope that you can postpone the
symptoms and misery as long as possible. Because
he had no symptoms which we had to do something
about. And, yes, in his case prolongation of life was
certainly a goal.”—Physician 7 (university hospital)
Second or third line chemotherapy often had lower
response probability and more severe side effects,
which complicated the treatment decision making in
the late stages of the disease. Arguments often used to
justifycontinuingwithtreatment(ifinaccordancewith
the patient’s wish) were the difficulty of predicting
treatment outcomes for individual patients and posi-
tive experiences with chemotherapy in situations that
were initially unpromising. It thus seems that rational
arguments are not over-riding in deciding whether
treatment is not in a patient’s interests.
Cooperative patients, cooperative physicians
The way physician and patient interact seems to drive
the provision of chemotherapy in the final stages of
disease because the patients’ and physicians’ attitudes
of “not giving up” seem to be mutually reinforcing.
The fact that patients have become better informed
about treatment options through media and internet
was highly appreciated by physicians and nurses, as
thismadeitpossibletoachievegreaterequalityinmak-
ing treatment decisions and understanding about pos-
sible treatment courses. Nevertheless, physicians and
nurses regarded patients as a cooperative group;
patients still usually followed their physicians’ advice
abouttreatment.Onephysiciansaidthatpatientsactu-
ally get scared when they really have to decide for
themselves.
Interviewer: “And how do patients react to that, that
they themselves can choose?”
Respondent: “Frightening. Yes, it always scares
them: ‘How can you make a choice like that?’ Yes.
Well, sometimes there simply isn’t any best option,
and then the patient can certainly decide for
himself. Often I have an opinion and I will say what
I think, and usually that is the choice that is made.
But sometimes there is simply no best option, and to
my mind you can just as well do either. And then
they can choose for themselves.”—Physician 14
(general hospital)
Withpatientsbeingbetterinformed,bothphysicians
and nurses reported that clear communication about
treatment options—with the prognosis and the advan-
tages and disadvantages of treatments carefully
explained—was of the utmost importance. They were
aware of the fact that the way they motivated their rea-
sons for providing further treatment could determine
whether a patient agrees to continuation of treatment.
“Yes, as long as you have good reasons … and what
I just said, if an oncologist says, ‘We’ll just give you
a short course of chemotherapy,’ that already
sounds a lot different from saying. ‘We’re going to
use chemotherapy, and this is what it entails, these
are the side effects,’ and a person sees that quite
differently.”—Nurse 13 (general hospital)
Apart from being open and honest with their
patients, physicians did not want to disappoint their
patients by not helping them or by taking away their
hope by giving them “nothing.” Patients’ wellbeing
wasconsideredextremelyimportant.Somephysicians
adaptedthemannerinwhichtheyofferedtreatmentto
match their patients’ preferences. Thus, patients were
regarded as cooperative with health professionals, but
physicians themselves seemed to be cooperative with
patients.
“Yes, you know, you don’t come out with ‘It’s
going badly,’ you just don’t.… You certainly don’t
do that with patients, and especially not with such a
young girl who is also extremely anxious and scared
of suffocating. And that is a real prospect. The
tumour is there, and it is a really enormous tumour
and presses on everything. And after all, every time
I came with some bad news, but even so a little bit
of good news.”—Physician 11 (university hospital)
“I understand it from the physician’s point of view
because you are so keen to offer something, people
want to hear something, but sometimes it goes too
far for me, yes.”—Nurse 11 (general hospital)
Physicians’ inclination to be cooperative could
explain why speaking about death or dying rarely
came up during consultations, and nearly always only
in the final stage of the disease. A substantial propor-
tion of the physicians stated that giving chemotherapy
and simultaneously speaking about the dying process
was too much of a contradiction, and that such discus-
sions would negatively affect the patient’s wellbeing.
Someofthenurses,however,saidthattheyconsidered
speaking about death and dying confrontational and
therefore difficult to initiate.
“We know from experience that if you talk about it
[death, dying] in a very early stage that people find
that very hard to take. So yes ... I bring it up later in
the process, if I think, ‘Now it could be relevant in
the relatively near future.’”—Physician 3 (university
hospital)
Interviewer: “Yes, but is it exceptional, that you
have conversations of that kind [about death,
dying]?
Respondent: “Well, that depends on the patient.
You more often ... I think that it also depends an
awful lot on your own nerve. You have to have the
nerve to start talking about it, as it were, and just put
it into words.”—Nurse 4 (general hospital)
According to the physicians and nurses, options for
further treatment seemed to be interpreted by patients
as signs of hope. Just as physicians tried to anticipate
what patients wanted, so patients seemed to anticipate
whattheythoughtphysicianswanted.Thus,according
to physicians but particularly to the nurses, patients
were often more optimistic about their medical condi-
tion towards their physician, hoping for further treat-
ment options.
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anymore, but he always wanted to keep the option
of chemotherapy open. It gave him hope.”—
Physician 4 (university hospital)
“That is our [nurses’] idea rather. If they say to the
physician, ‘Dear me, I really don’t feel well and I
don’t know whether I can cope with this whole
process,’ then it seems that if they say the same
thing to me they are much less non-committal than
when they say that to a physician, or it’s easier to
say it to me because I’m not going to stop the
course of treatment.… But with the physician, it
would appear that they think that he can say, ‘Oh,
then we’ll just stop’ or something.”—Nurse 2
(university hospital)
Ambivalence
Physicians and nurses were eager to grant patients’
wishes for treatment, to preserve hope and to prolong
life as much as possible, but they also sometimes
doubted whether further treatment would contribute
to the patients’ quality of life. Similarly, they did not
want to take away patients’ hope by discussing death
and dying while giving chemotherapy, but they rea-
lised that delaying such discussions reduced their
patients’ time to accept death and to say farewell.
“And we certainly don’t start [discussions about
death, dying] at that point because you are indeed
administering a course of chemotherapy. Yes. But
that means therefore that if you keep going on in
that way, ultimately someone will have a very short
period of time to really say farewell.”—Physician 8
(general hospital)
Physicians and nurses seemed to find greatest diffi-
culty with the “grey area” in which a patient’s medical
condition would theoretically permit another line of
chemotherapy, and the patient explicitly wants the
treatment, but they would, balancing the treatment
benefits and burdens, advise against it.
“Yes, it’s difficult when you do it and when you
don’t [prescribe another course of chemotherapy]....
When it’s down to the last wire and someone wishes
for treatment, I simply think, ‘Let’s get on with
this.’ ... There have also been patients that make
you think, “If I don’t act now, they could be gone
within days.”—Physician 6 (university hospital)
All physicians and nurses sometimes had these
ambivalent feelings but most often in situations where
patients wanted to continue fighting and would accept
any kind of treatment as a last straw to prolong life.
They reported that, despite repeated conversations
with physicians and nurses, these patients did not
want to talk or think about death and dying at all. The
physicians and nurses were caught between providing
a treatment that could be considered invasive and too
burdensomeforpatientsatthisstageofthediseaseand
refusing to give it, which could cause unbearable suf-
fering for these patients.
“So he seemed to think, ‘If I stop now then it’s
finished for me. I can’t go home and sit and wait
until I die.’ That’s how they explain it.”—Physician
10 (general hospital)
However, patients also sometimes seemed to be
ambivalentabouttheirtreatmentpreferences:towards
physicians and nurses, but also towards themselves.
Physicians and nurses reported that patients some-
times would speak freely with nurses about how they
felt and what they feared, but would simultaneously
ask their physicians for further treatment. Further-
more, they sometimes behaved towards physicians
and nurses as if they were ignorant of their poor prog-
nosis and life expectancy, but the physicians and
nurses questioned whether this was truly ignorance or
“not wanting to know.”
“I suppose so ... but I think it’s sometimes really
hard to tell whether people really don’t know or
don’t want to know.… I tend to think, rather, that
more often they repress it than that they don’t hear.
That it’s a coping mechanism that the people
themselves adopt.”—Nurse 7 (general hospital)
Nurses more often seemed to be ambivalent about
further treatment than physicians. Whenever physi-
cians had ambivalent feelings, they rarely chose to
refuse treatment explicitly but tried to reach a shared
decision,whichcouldalsobeacompromise.Theypre-
ferred to suggest a mild alternative, to “try out one
dose,” or to advise a patient to consult another physi-
cian in another hospital rather than explicitly refuse
treatment. Having the possibility of “Just try and see
how it goes” was regarded as a great advantage of che-
motherapy (every line consists of several doses).
“You could say ‘Let’s try one course of treatment
and then see how it goes, how many side effects
there are.’... There’s no question of that in the case
of resuscitation; a resuscitation is black and white,
you do it or you don’t. And in the case of
chemotherapy you say, ‘Well, perhaps we could try
it.’”—Physician 9 (general hospital)
Ways to interrupt patients’ and physicians’ mutually
reinforcing attitudes of “not giving up”
Physicians generally reported little difficulty in with-
holding treatment when a patient’s medical condition
was clearly insufficient to start another line of che-
motherapy. The same held for situations in which
patients and physicians together came to the conclu-
sion that further treatment would no longer be benefi-
cial. This was not the case in “grey area” situations,
however. Although a substantial proportion of the
physiciansadmittedbeinginclinedtoprescribefurther
treatment in such situations, they seemed unsure
whether and when they should switch towards purely
symptom-directed care.
Topreserveapatient’squalityoflife,physiciansand
nurses however had made up their minds how to with-
hold further treatment in grey area situations. Only a
few, mainly younger physicians, said that, in being
responsible for a patient’s quality of life, it is the physi-
cian’s task to explicitly refuse the patient’s wishes for
further treatment in grey area situations. Conversely,
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communication and sufficient information about
what patients could expect from future treatment
could abate patients’ wishes for treatment in grey
area situations.
“If you say at a certain point in the case of an illness
for which there are different courses of treatment
available, ‘You’re making progress, I can still treat
you, but the number of options is now diminishing.
I have two more possibilities but then that’s it,’ then
you are actually announcing a year or six months in
advance that that point in time is approaching.
While if you deliberately choose not to discuss it at
that moment ... either because of the time aspect or
because you think you have a different opinion and
will thus impose a burden on the patient, then the
blow comes much harder at the point when you
have to say it.”—Physician 13 (general hospital)
Furthermore, some physicians explicitly mentioned
that they provided the option of “doing nothing”
together with treatment options during bad news con-
sultations.Physiciansand,inparticular,nursesstressed
the importance of carefully explaining the meaning of
“nothing.” Physicians’ use of technical jargon could
sometimes be misinterpreted by patients, and then
could result in an even stronger wish for “something.”
“For me it is always a very clear option [not starting
chemotherapy], and not everyone thinks the same
way about this.… And if people are really in a poor
state, or if they are older and they have a metastatic
disease, then I think that ‘doing nothing’ is often a
good option, because then you substantially retain
the quality of life.”—Physician 14 (general hospital)
Despite these ideas about how to prevent the pre-
scription of burdensome treatment, one physician
reported seeing in colleagues how an attending physi-
cian and patient often slowly grew together during the
courseofthedisease.Thisemotionalbondunderstand-
ablymadeit difficultforthe attendingphysiciantodis-
engage from the physician’s and patient’s shared
intention “not to give up.” During the course of treat-
ment, patients as well as physicians hoped for the best.
“And that you’re in a situation … where the patient
together with the oncologist is so dug in, that
together they are hanging on to life for all they are
worth. And then you have little opening to get
something moving.”—Physician 1 (university
hospital)
Such observations were also made by some of the
nurses. Nurses, however, sometimes presumed that
physicians would not seriously listen to them if they
voicedtheirconcerns.Physicians,incontrast,reported
greatly appreciating nurses’ contributions—for exam-
ple,inprovidinginformationaboutapatient’spsycho-
social situation. Nurses saw their role as someone who
reassures and supports patients, who further explains
the information given by the physician, and who
informs physicians when patients are deteriorating.
Some of the nurses also felt they had an important
role in protecting patients from further treatment with
burdensome side effects, for instance by assisting
patients in preparing questions they could address to
their physician.
Interviewer: “And did they [physicians] listen to this
[nurses’ concerns about continuation of treatment]?
Respondent: “Yes … they did … but they wanted to
continue with this very last option. So, they listened
to our concerns, but they nevertheless continued.”—
Nurse 11 (general hospital)
“Well, yes, in that sense, as a nurse, you are
sometimes rather in the middle, and that’s not a bad
thing. As a nurse, you have more contact with the
patient than a physician, so in that sense you can
assess the non-clinical aspects better than a
physician. And you can talk about that with a
physician, if the patient can’t. Or be supportive to
the patient in this respect.”—Nurse 4 (general
hospital)
DISCUSSION
Out of fear of negatively affecting the wellbeing of a
patient with end stage cancer, physicians seem to be
inclined to offer further treatment and to strive for
prolongingthepatient’slife.Nurses,however,seemed
to be inclined to express their doubts concerning
further treatment to allow patients to make the best
use of the time that is left. Physicians’ emphasis on
treatment can be explained by patients’ and physi-
cians’ mutually reinforcing attitudes of “not giving
up,” and by their broad interpretation of a patient’s
quality of life, in which taking away the patient’s
hope by withholding treatment is considered harmful.
Physiciansemphasisontreatmentandtheirfeelingthat
discussing death or dying at the same time as adminis-
tering chemotherapy was considered contradictory
make withholding treatment in an earlier stage in the
course of the disease difficult.
Strengths and weaknesses of study
A feature that increases the validity of this study is the
purposivesamplingacrosssettings(universityandgen-
eralhospitalsintheNetherlands)andacrossdisciplines
(physicians and nurses with various backgrounds).
Taking the perspectives of both physicians and nurses
into account offers further insight into the reasons
behind treatment decisions.
Our study also has limitations. Part of our study
describes the way physicians and nurses interacted
with their patients. The most appropriate study design
for this would have been a combination of observa-
tional study and interviews, including interviews with
patients. However, observing consultations in situa-
tions in which the patient is near the end of life is ethi-
cally problematic.
Anotherlimitationofourstudyisthatwefocusedon
“difficult” and “straightforward” cases rather than on
the type of cancer; our study may therefore not be
representative for the whole cancer population. How-
ever, physicians’ underlying reasons to withhold che-
motherapy is best illustrated with atypical patient
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3 By asking physicians and nurses about straight-
forward cases also, we were able to find out how they
themselvesdistinguishedbetweenstraightforwardand
difficult situations. Situations in which health profes-
sionals and patients had contrasting ideas about treat-
ment (mostly when patients persisted in wanting
treatment) were often considered difficult and the
most unsatisfactory in hindsight; the differences were
not dependent on the type of cancer.
Finally,thefactthattheprimaryresearcherhadcon-
ductedalloftheinterviewsandhadcodedthemajority
of them could be considered as a limitation of the
study.
The provision of chemotherapy at the end of life: medicine
on demand?
Variousstudieshavedepicteda trendtowardsincreas-
ing use of chemotherapy for patients with end stage
cancer,
589 and doubts about the benefits of such use
are rising. This raises the question of why this trend
exists and whether it is the result of greater demand
from patients—that is, respect for this demand from
physicians. In the past decade, the patient’s role and
patient autonomy in end of life decisions have been
extensively discussed.
1819 Our study findings suggest
that greater attention towards patient autonomy is not
the key explanatory factor of increasing use of che-
motherapy at the end of life. Instead, this trend could
first of all be explained by patients’ and physicians’
mutually reinforcing attitudes of “not giving up.”
It seems that physicians are inclined to offer further
treatment to strive to prolong a patient’s life, and they
do not want to disappoint patients who explicitly wish
for treatment by taking away their hope. Patients, in
turn, eagerly follow their physicians’ well meant offers
of treatment, which they seem to interpret as a sign of
hope. Patients and physicians thus seem to mutually
reinforce the continuation of treatment. This shared
intention not to “give up” seems to be strengthened
by the intense physician-patient relationship that
develops and by the nature of chemotherapy itself—
deciding about chemotherapy is not a clear-cut deci-
sion and includes many options.
20 Physicians (con-
sciously or unconsciously) seemed to be hesitant to
force a break from cancer treatment (and thus a switch
tocomfortcare).Thismaypartlybeexplainedbyphy-
sicians’reluctancetoinitiatediscussionsaboutdeathor
dying while administering treatment. It also seemed
that breaking from cancer treatment was not possible
at all with patients who did not accept their own mor-
tality.
What is in the patient’s best interests?
Physicians took account of various aspects of a
patient’s situation in their decision making, as has
been reported by Van Leeuwen et al.
21 In “grey area”
situations, a substantial proportion of the physicians
admitted they preferred to continue treatment rather
than explicitly withholding it despite sometimes
doubting whether the treatment benefits would out-
weigh the burdens. Yet, physicians only sometimes
referred to chemotherapy as treatment that was not in
apatient’sinterest,althoughprofessionalmedicalstan-
dards describe that treatment should do as little harm
as possible.
22
Wefoundthatthenursesmorefrequentlyseemedto
question whether further treatment would be in a
patient’s best interest. In “grey area” situations, they
also admitted to sometimes doubt the benefits of
further treatment. However, on balance, instead of
continuation of treatment, they seemed to prefer that
patients be allowed to make the best use of the time
they had left. This difference in attitude is not particu-
larly surprising
23 since nurses often heard a different
patient story from that told to physicians—a story in
which patients’ doubts about further treatment were
more pronounced. Moreover, nurses are differently
schooled and have different responsibilities towards
patients than physicians. In general, nurses are more
inclined to focus on the consequences of cancer and
cancer treatment for patients’ and relatives’ lives in
the broadest sense, whereas physicians are more
inclined to focus on the patient’s present physical and
mental condition and on the consequences of treat-
ment.
However, there is no generally accepted definition
of what is in a patient’s best interests nor a practical
guideline for determining it.
24 Physicians seemed to
use a broader interpretation of a patient’s quality of
life, in which taking away the patient’s hope by with-
holdingtreatmentwas consideredharmful.Thephysi-
cians’broadnotionofpatients’qualityoflife,andtheir
occasional positive experiences with chemotherapy
when they were initially unsure about its effectiveness,
mayexplainwhytheyrarelyreferredtochemotherapy
as treatment that is not in a patient’s interest. Our data
suggest that nurses’ idea about the usefulness of che-
motherapy was sometimes more accurate than that of
physicians, since physicians held that doing “some-
thing” and never give up hope, especially in the final
stages of the disease, was sometimes more important
than the expected treatment outcome. Nevertheless,
ourdataalsoshowedthatinrarecasesprovidingprob-
ably ineffective treatment may be beneficial for the
patient.
Research and implications for clinicians and policy makers
Our findings have direct relevance for discussions
about the increasing use of chemotherapy in end
stagecancer.Theyarealsoapplicabletoothermedical
settings, since overuse of treatment—from diagnostic
tests to new forms of screening—receive wide
attention.
25 To initiate a behavioural change in physi-
cians’ emphasis on treatment, three aspects demand
further attention.
(1) Physicians’ inclination to preserve a patient’s
hope by offering further treatment is understandable.
Retaining hope allows patients to continue to focus
their minds on aspects that give meaning to their
lives.
26 Our findings suggest that, although physicians
try to inform patients accurately about the severity of
theirdisease,theydonotwanttotakeawaytheirhope,
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ment options or by evading end of life discussions.
Physicians sometimes give partial information to
ensure that patients stay optimistic about recovery,
and patients retain their unrealistic hope by a biased
listening to their physicians.
1727 A moral evaluation is
neededtoexplorewhetheritisalwaysdesirabletopre-
serve patients’ hope if that is based on unrealistic
expectations.
(2) The physicians in our study considered a discus-
sion about a patient’s approachingdeath while admin-
istering treatment to be contradictory, which makes
withholding treatment at an earlier stage of the cancer
disease trajectory even more difficult. Our findings
suggest that there may be a role for other healthcare
professionals to interrupt patients’ and physicians’
shared intention of “not giving up,” perhaps by timely
initiation of end of life discussions. An earlier switch
from active (disease directed) treatment to comfort
(symptom directed) treatment would shorten the
course of chemotherapy. Future research should
focus on how such interruption of patients’ and physi-
cians’ mutually reinforcing attitudesshould be accom-
plished. Simultaneously, a moral evaluation is needed
to explore whether such interruption is always the
most beneficial approach for patients, especially for
patients who want to go on till the very end.
(3) Physicians seem to have a less restrictive attitude
towards continuation of treatment than nurses, which
could partly be explained by nurses having a better
understanding of their patients’ feelings. Our findings
suggest that improving communication between phy-
sicians and nurses could result in a more realistic
mutualunderstandingofapatient’smedicalcondition.
In addition, media communication about the negative
outcomesofcancertreatmentaswellasadequateinfor-
mation about end of life care would probably widen
patients’ and physicians’ ideas about treatment. A
recent US study, however, showed that news reports
about cancer often discussed aggressive treatment
and the chances of response but rarely discussed treat-
ment failure, adverse events, and end of life care or
death.
28 This too merits attention from a health policy
perspective.
We thank K Davis, M Stapel, FE Witkamp, and MA Buiting for their
valuablecontributionsto thestudydesignandintheinterpretationofthe
studyfindings.Wealsothankthephysicians andnurseswhoparticipated
in this study.
Contributors: HMB, MLR, HW, and GdH designed the study. HMB carried
outthestudy.HMB,MLR,HW,GdH,andLvZwereinvolvedininterpreting
the study findings. HMB wrote the manuscript, which was critically read
by all the authors. HMB is guarantor of the study. All authors had full
access to all the data in the study and can take responsibility for their
integrity and the accuracy of their analysis.
Funding: This study was supported by a grant from ZonMw, the
Netherlands Organization for Health Research and Development (grant
No 70-71300-98-048). The study sponsor had no role in the study
design;collection,analysis,andinterpretationofthedata;orinthewriting
of the article and decision to submit the article for publication.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare: HMB, MLR, HW, and GdH
have support from the University of Amsterdam for the submitted work;
the authors have no relationships with any company that might have an
interest in the submitted work in the previous 3 years; and no other
relationships or activities that could appear to have influenced the
submitted work.
Ethical approval: Not required.
Data sharing: No additional data available.
1 StewardWP,DunlopDJ.Newdrugsinthetreatmentofnon-smallcell
lung cancer. Ann Oncol 1995;6(suppl 1):49-54.
2 Punt CJ. New drugs in the treatment of colorectal carcinoma. Cancer
1998;83:679-89.
3 The AM, Hak T, Koeter G, van Der Wal G. Collusion in doctor-patient
communication about imminent death: an ethnographic study. BMJ
2000;321:1376-81.
4 Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS.
Chemotherapy use among Medicare beneficiaries at the end of life.
A n nI n t e r nM e d2003;138:639-43.
5 Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ.
Aggressiveness of cancer care near the end of life: is it a quality-of-
care issue? JC l i nO n c o l2008;26:3860-6.
6 Barnato AE, McClellan MB, Kagay CR, Garber AM. Trends in inpatient
treatment intensity among Medicare beneficiaries at the end of life.
Health Serv Res 2004;39:363-75.
7 Grady D, Redberg RF. Less is more: how less health care can result in
better health. Arch Intern Med 2010;170:749-50.
8 Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC.
Trendsintheaggressivenessof cancercareneartheend oflife.J Clin
Oncol 2004;22:315-21.
9 Braga S, Miranda A, Fonseca R, Passos-Coelho JL, Fernandes A,
Costa JD, et al. The aggressiveness of cancer care in the last three
months of life: a retrospective single centre analysis.
Psychooncology 2007;16:863-8.
10 Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, et al.
Attitudes to chemotherapy: comparing views of patients with cancer
with those of doctors, nurses, and general public. BMJ
1990;300:1458-60.
11 Lantos JD, Singer PA, Walker RM, Gramelspacher GP, Shapiro GR,
Sanchez-GonzalezMA,etal.Theillusionoffutilityinclinicalpractice.
Am J Med 1989;87:81-4.
12 Grant L, Murray SA, Sheikh A. Spiritual dimensions of dying in
pluralist societies. BMJ 2010;341:c4859.
1 3 M a c kJ W ,W e e k sJ C ,W r i g h tA A ,B l o c kS D ,P r i g e r s o nH G .E n d - o f - l i f e
discussions, goal attainment, and distress at the end of life:
predictors and outcomes of receipt of care consistent with
preferences. JC l i nO n c o l 2010;28:1203-8.
14 Ritchie J, Lewis J, Elam G. Designing and selecting samples.I n :
RitchieJ,LewisJ,eds.Qualitativeresearchpractice:aguideforsocial
science students and researchers. Sage Publications, 2007.
15 Pope C, Ziebland S, Mays N. Qualitative research in health care.
Analysing qualitative data. BMJ 2000;320:114-6.
16 Buiting HM, Rietjens JA, Onwuteaka-Philipsen BD, van der Maas PJ,
v a nD e l d e nJ J ,v a nd e rH e i d eA .Ac o m p a r i s o no fp h y s i c i a n s ’ end-of-
life decision making for non-western migrants and Dutch natives in
the Netherlands. Eur J Public Health 2008;18:681-7.
17 Spencer L, Ritchie J, O’Connor W. Analysis: practices, principles,
processes. In: Ritchie J, Lewis J, eds. Qualitative research practice: a
guideforsocialsciencestudentsandresearchers.SagePublications,
2007.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Deciding whether to administer chemotherapy in end stage cancer is not a clear cut decision
but includes many options
Studies have reported a trend toward increasing use of chemotherapy at the end of life
WHAT THIS STUDY ADDS
Physicians’ and nurses’ attitudes towards patients with end stage cancer seem to be
expressed differently: physicians are more inclined to offer further treatment to strive to
prolong patients’ lives,whereas nursesare more doubtful about further treatment,preferring
that patients be allowed to make the best use of the time that is left
Patients and physicians seem to mutually reinforce each other’sa t t i t u d e so f“not giving up,”
which leads to an emphasis on continuation of treatment
Discussionabout a patient’s approaching death while administering treatment isconsidered
contradictory as this could diminish the patient’s hope, which makes withholding treatment
at an earlier stage of the disease even more difficult
RESEARCH
page 8 of 9 BMJ | ONLINE FIRST | bmj.com18 Dreyer A, Forde R, Nortvedt P. Autonomy at the end of life: life-
prolonging treatment in nursing homes–relatives’ role in the
decision-making process. J Med Ethics 2009;35(11):672-7.
19 Zanchetta MS, Moura SL. Self-determination and information
seeking in end-stage cancer. Clin J Oncol Nurs 2006;10(6):803-7.
20 De Kort SJ, Pols J, Richel DJ, Koedoot N, Willems DL. Understanding
palliative cancer chemotherapy: about shared decisions and shared
trajectories. Health Care Anal 2010;18:164-74.
21 Van Leeuwen AF, Voogt E, Visser A, van der Rijt CC, van der Heide A.
Considerations of healthcare professionals in medical decision-
making about treatment for clinical end-stage cancer patients. JP a i n
Symptom Manage 2004;28:351-5.
22 Beauchamp T, Childress J. Principles of biomedical ethics.O x f o r d
University Press, 2001.
23 Breier-Mackie S. Patient autonomy and medical paternity: can
nurseshelpdoctorstolistentopatients?NursEthics2001;8:510-21.
24 Schneiderman LJ, Jecker N. Futility in practice. Arch Intern Med
1993;153:437-41.
25 Ablin RJ, Sartor O, Bennett CL. Invited commentary: prostate cancer:
doing less might be more. Comment on “Severity of comorbidity and
non-prostate cancer mortality in men with early-stage prostate
cancer”. Arch Intern Med 2010;170:1397-9.
26 Vos T. Denial and quality of life in lung cancer patients. PhD Thesis
University of Amsterdam, 2009.
27 KirkP,KirkI,KristjansonLJ. Whatdopatientsreceivingpalliativecare
for cancer and their families want to be told? A Canadian and
Australian qualitative study. BMJ 2004;328(7452):1343.
28 Fishman J, Ten Have T, Casarett D. Cancer and the media: how does
the news report on treatment and outcomes? Arch Intern Med
2010;170:515-8.
Accepted: 20 March 2011
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 9 of 9